Tumour lysis syndrome: new therapeutic strategies and classification - PubMed (original) (raw)
Review
Tumour lysis syndrome: new therapeutic strategies and classification
Mitchell S Cairo et al. Br J Haematol. 2004 Oct.
Free article
Abstract
Tumour lysis syndrome (TLS) describes the metabolic derangements that occur with tumour breakdown following the initiation of cytotoxic therapy. TLS results from the rapid destruction of malignant cells and the abrupt release of intracellular ions, nucleic acids, proteins and their metabolites into the extracellular space. These metabolites can overwhelm the body's normal homeostatic mechanisms and cause hyperuricaemia, hyperkalaemia, hyperphosphaetemia, hypocalcaemia and uraemia. TLS can lead to acute renal failure and can be life-threatening. Early recognition of patients at risk and initiation of therapy for TLS is essential. There is a high incidence of TLS in tumours with high proliferative rates and tumour burden such as acute lymphoblastic leukaemia and Burkitt's lymphoma. The mainstays of TLS prophylaxis and treatment include aggressive hydration and diuresis, control of hyperuricaemia with allopurinol prophylaxis and rasburicase treatment, and vigilant monitoring of electrolyte abnormalities. Urine alkalinization remains controversial. Unfortunately, there have been few comprehensive reviews on this important subject. In this review, we describe the incidence, pathophysiological mechanisms of TLS and risk factors for its development. We summarise recent advances in the management of TLS and provide a new classification system and recommendations for prophylaxis and/or treatment based on this classification scheme.
Copyright 2004 Blackwell Publishing Ltd
Similar articles
- An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome.
Mughal TI, Ejaz AA, Foringer JR, Coiffier B. Mughal TI, et al. Cancer Treat Rev. 2010 Apr;36(2):164-76. doi: 10.1016/j.ctrv.2009.11.001. Epub 2009 Dec 23. Cancer Treat Rev. 2010. PMID: 20031331 Review. - Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.
Cairo MS, Coiffier B, Reiter A, Younes A; TLS Expert Panel. Cairo MS, et al. Br J Haematol. 2010 May;149(4):578-86. doi: 10.1111/j.1365-2141.2010.08143.x. Epub 2010 Mar 16. Br J Haematol. 2010. PMID: 20331465 Review. - Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.
Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Coiffier B, et al. J Clin Oncol. 2008 Jun 1;26(16):2767-78. doi: 10.1200/JCO.2007.15.0177. J Clin Oncol. 2008. PMID: 18509186 Review. - Tumor lysis syndrome in elderly.
Pumo V, Sciacca D, Malaguarnera M. Pumo V, et al. Crit Rev Oncol Hematol. 2007 Oct;64(1):31-42. doi: 10.1016/j.critrevonc.2007.05.003. Epub 2007 Jul 19. Crit Rev Oncol Hematol. 2007. PMID: 17658268 Review. - [Tumor lysis syndrome].
Jeddi R, Ben Abdennebi Y, Allani B, Belakhal R, Aissaoui L, Ben Abid H, Ali ZB, Meddeb B. Jeddi R, et al. Tunis Med. 2007 Feb;85(2):174-6. Tunis Med. 2007. PMID: 17665670 Review. French.
Cited by
- Investigating Effects of Acidic pH on Proliferation, Invasion and Drug-Induced Apoptosis in Lymphoblastic Leukemia.
Bohloli M, Atashi A, Soleimani M, Kaviani S, Anbarlou A. Bohloli M, et al. Cancer Microenviron. 2016 Dec;9(2-3):119-126. doi: 10.1007/s12307-016-0187-0. Epub 2016 Jul 25. Cancer Microenviron. 2016. PMID: 27457339 Free PMC article. - Outcomes in Critically Ill Patients with Cancer-Related Complications.
Torres VB, Vassalo J, Silva UV, Caruso P, Torelly AP, Silva E, Teles JM, Knibel M, Rezende E, Netto JJ, Piras C, Azevedo LC, Bozza FA, Spector N, Salluh JI, Soares M. Torres VB, et al. PLoS One. 2016 Oct 20;11(10):e0164537. doi: 10.1371/journal.pone.0164537. eCollection 2016. PLoS One. 2016. PMID: 27764143 Free PMC article. - Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience.
Takai M, Yamauchi T, Matsuda Y, Tai K, Ikegaya S, Kishi S, Urasaki Y, Yoshida A, Iwasaki H, Ueda T. Takai M, et al. Oncol Lett. 2015 May;9(5):2119-2125. doi: 10.3892/ol.2015.3009. Epub 2015 Mar 3. Oncol Lett. 2015. PMID: 26137024 Free PMC article. - Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report.
Baudon C, Duhoux FP, Sinapi I, Canon JL. Baudon C, et al. J Med Case Rep. 2016 Jun 16;10:178. doi: 10.1186/s13256-016-0969-5. J Med Case Rep. 2016. PMID: 27312594 Free PMC article. - How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.
Jonas BA, Pollyea DA. Jonas BA, et al. Leukemia. 2019 Dec;33(12):2795-2804. doi: 10.1038/s41375-019-0612-8. Epub 2019 Oct 18. Leukemia. 2019. PMID: 31628431 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources